Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nova Scotia releases more funds in moves to double number of scanners:

This article was originally published in Clinica

Executive Summary

Capital Health, one of Nova Scotia's nine health districts, is to purchase a positron emission tomography (PET) scanner under a Can$5.5m (US$4.4m) programme. The scanner, which incorporates a CT machine, will be purchased this year, to be installed and operational within two years. The provincial government will contribute Can$3m, communications company Aliant and a group of diagnostic imaging physicians (based at the QEII Health Sciences Centre, Halifax) Can$500,000 each, and the QEII Foundation (the funding arm of the QEII) Can$1.5m. The funds will also purchase a radiopharmacy. Plans to develop a cyclotron for the Atlantic region are also in place. The acquisitions are in line with Nova Scotia's budget plans to double the amount of scanners in the province. The government is aiming at one MRI scanner per 117,500 people.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT055601

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel